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days. Among patients with an HbA1c value post-index (N =
118), 28% reached the ADA target level of 7% or less. CON-
CLUSIONS: High pre-index HbA1c values may have con-
tributed to the relatively low proportion of T2D patients
achieving HbA1c goal after initiating glargine. This suggests an
opportunity for earlier and more aggressive pharmacotherapy
management of patients with T2D.
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GlucoWatch® Biographer G2TM (GWG2), in comparison to
standard self-monitoring of blood glucose. METHODS: Medline
MeSH heading searches of the published peer-reviewed clinical
literature identiﬁed all relevant studies since 2001. Technologies
were evaluated based on their ability to provide clinically accu-
rate glucose readings and improve glycemic control and overall
health outcomes. RESULTS: The available data surrounding
these devices is limited at this time because only GWG2 and GRT
are currently FDA approved. GWG2 demonstrated less than ade-
quate accuracy and a high false-positive rate (50–73%). DAY,
GRT and DEX demonstrated acceptable overall accuracy in
Clarke Error Grid studies (>95% zones A + B), however NAV is
the most accurate of the RTCGMs (99% overall, 92.4% during
hypoglycemia). Signiﬁcant data surrounding the effects of DAY,
DEX and NAV on glycemic control was not found, however
GWG2 was shown to have no positive, and perhaps a negative,
effect on glycemic control. Limited evidence with GRT revealed
a decrease in the frequency and duration of hypo- and hyper-
glycemic excursions. GWG2 which reported excessive skin irri-
tation in up to 76% of patients, often requiring discontinuation
of use, however the other RTCGMs displayed no signiﬁcant
adverse event occurrence. CONCLUSION: Given the limited evi-
dence presented in this assessment and based on its design and
preliminary clinical data, it appears that NAV is the most favor-
able of the RTCGMs. Fulﬁllment of customary health technol-
ogy assessment criteria will require FDA approval and additional
data documenting successful implementation.
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OBJECTIVE: Patient-interactive, real-time continuous glucose
monitors (RTCGMs) represent the future of diabetes manage-
ment and have the potential to improve health outcomes and
reduce diabetes-related complications. This assessment will eval-
uate the net health outcomes obtained in patients with insulin-
dependent diabetes while using RTCGMs such as the FreeStyle
NavigatorTM (NAV), GlucoDay® S (DAY), Guardian® RT
(GRT), DexComTM STSTM and Long-Term Systems (DEX) and
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